Our extensive experience in health technology assessment (HTA) through providing strategic advice and guiding evidence generation to support submissions to UK HTA bodies, enables us to provide you with a tailored solution to reimbursement and patient access.
Cost‑Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective